Senior Fellows


A professor at the University of Paris School of Medicine, Gregory Katz[1] holds the Chair of Innovation & Value in Health[2]. He is founding director of the VBHC Consortium, a nonprofit dedicated to accelerating the emergence of Value-Based Health Care (VBHC) to enable medical teams to compare and improve patient outcomes. He has served as director of research and innovation at some of the leading private hospital groups in Europe. His scientific publications focus on innovation management in life sciences, and more specifically on patient-reported outcome measures (PROMs) and value-based partnerships. He works on a regular basis with the French Health Authorities on a series of organizational innovations ranging from the development of public cord blood banks, to disruptive VBHC models designed to incentivize practitioner transparency on patient outcomes. In 2019-2020, EIT Health – a body of the European Union – commissioned Katz to publish a report entitled Implementing Value-Based Health Care in Europe: Handbook for Pioneers. From 2003-2005, he was Visiting Professor at INSEAD in Fontainebleau & Singapore. From 2004 to 2015, he was Chaired Professor of Therapeutic Innovation and Co-director of the Institute for Health Economics & Management at ESSEC Business School (Paris-Singapore). His pro bono activities include Vice-President of the Eurocord (2004-2008), a scientific nonprofit conducting clinical research on cord blood transplantation in more than 500 transplant centers across 56 countries. He was a board member of the European School of Surgery (2009-2012), Chairman of the Scientific Board of the GlaxoSmithKline Vaccines Global Innovation Fund (2012-2015), and Chairman of the think tank Digital Leaders in Health (2018). In 2020, he was member of the global board of experts for Newsweek’s World’s Best Hospitals ranking. He is the recipient of several awards, including the San Benedetto International Prize for his achievements in bioethics and humanism (2009), the Special Jury Award from the French Fédération de l’Hospitalisation Privée (2012), and was guest of honor of the Grand Rounds Lecture at the UCLA Fielding School of Public Health (2015).



Daniel S. Levine

Daniel S. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his career. He founded Levine Media Group in 2013 to provide strategic communications to life sciences companies. He hosts The Bio Report and RARECast podcasts and is a member of the advisory board of the California Biotechnology Council.

Levine previously served as managing director of publications for Burrill & Company, a global financial services and media firm focused exclusively on the life sciences. There he led the media division and served as editor of The Burrill Report, a monthly digital publication focused on the business of the life sciences, and hosted the publication’s weekly podcast. He also served as the lead editor and writer of Burrill & Company’s acclaimed annual book on the biotech industry. His work with Burrill & Company began through the firm’s joint venture magazine startup The Journal of Life Sciences, where he led the creation of the publication’s web version and served as web editor before advancing to editor.

Prior to joining Burrill & Company, Levine worked as special projects editor for the San Francisco Business Times where he won numerous awards for his coverage of the biotechnology industry. His work has appeared in The New York Times, The Industry Standard,, and other national publications. His coverage of the biotechnology industry began at the start of his journalism career while a business reporter at The Oakland Tribune.

Before entering journalism, Levine spent five years in the investment banking industry and served as a vice president and general principal of Herbert Young Securities in Great Neck, New York. He holds a bachelor’s in English from Vassar College and a master’s in journalism from the University of California, Berkeley.

The Honorable Mike Ferguson

The Honorable Mike Ferguson is chairman and CEO of Ferguson Strategies LLC, a government affairs and business consulting firm based in Washington, D.C.  The Honorable Mike Ferguson served in the U.S. House of Representatives from 2001-2009, representing New Jersey’s 7th District.

In the House, Ferguson served as a member of the House Energy and Commerce Committee, which has wide jurisdiction over the health care, telecommunications and energy industries.  He served as vice chairman of the panel’s Health Subcommittee, as a member of the Telecommunications and the Internet Subcommittee, and as a member of the Oversight and Investigations Subcommittee.

While in Congress, Mike Ferguson also served as a member of the House Financial Services Committee, the Transportation and Infrastructure Committee, and the Small Business Committee.

Before entering the House, Mr. Ferguson was an educator and small business owner. He founded an education consulting firm that advocated school reform and scholarship programs. He taught history and coached basketball at a high school in the Bronx, New York and was an adjunct instructor of political science at a college in New Jersey.

A graduate of Delbarton School in Morristown, New Jersey, Mike Ferguson attended the University of Notre Dame, where he received a bachelor’s degree in government. He received a master’s of public policy degree with a specialization in education policy from Georgetown University in Washington, D.C.  He and his wife Maureen have four children.

J. Rick Turner, Ph.D.

Dr Rick Turner is an experimental research scientist who spent the first 15 years of his career in academic cardiovascular behavioral medicine research, investigating the putative role of behavioral stress in the etiology of hypertension.  He worked at three university medical schools, and published 50 papers in peer-reviewed journals in this research field.  He then moved into the pharmaceutical industry as a medical writer, running his own company, Turner Medical Communications LLC, and working for GlaxoSmithKline.

In 2005 he moved to the Campbell University School of Pharmacy (Research Triangle Park, NC) where he is Associate Professor of Clinical Research and the School’s Drug Safety Scholar.  His main areas of interest are the design and analysis of clinical trials, and the cardiac safety of noncardiac drugs.  He has recently published three books in these areas, and given several talks on cardiac safety at national meetings.  He is also a member of the Cardiac Safety Research Consortium.

Dr Turner is also very interested in communicating the scientific and clinical aspects of drug development and pharmacotherapy to the general public, and helping health journalists to report on these issues accurately and informatively.  He has been invited to participate in a workshop on “The Pitfalls of Reporting Clinical Trials” at the 6th World Conference of Science Journalists in London, June 2009, and looks forward to participating in more such ventures.

Gary Applebaum, M.D.

As Executive Vice President and Chief Medical Officer of Erickson Retirement Communities, Gary Applebaum developed and managed the largest group practice (Erickson Health) of geriatrics providers in America.

Gary lead the installation of Centricity (GE Health Care), a primary care electronic health record system, in less than a year at 10 practices in 7 states including data entry of over 10,000 patients' charts. To accomplish this, the team needed to train over 200 providers and staff members to use system. Erickson's practices are now paperless including all medical documentation, as well as orders and billing. For his efforts, Gary was named Geriatrics Clinician of the Year by the American Geriatrics Society recognizing the unique nature of the system of care developed at Erickson.

Currently, Dr. Applebaum continues to practice medicine at Levindale Hebrew Geriatric Center and Hospital. He received his M.D. from the University of Pennsylvania, trained at the Johns Hopkins University and is board certified in Internal Medicine and Geriatrics. He is also a partner and investor in an early stage venture capital fund, Nobska Ventures. In addition, he is a board member and Chairs, the Life Sciences Team of the Maryland/Israel Development Center for The Associated: - Jewish Community Federation of Baltimore, as well as serving as an advisory board member for the International Council on Active Aging. In 1992, Gary testified at a congressional hearing for the United States House of Representatives, Select Committee on Aging, Subcommittee on long-term care.

Dr. Applebaum ran for a seat in the US House of Representatives in Maryland to offer national leadership to improve health care for all Americans while decreasing the ever escalating cost of our system.  He has stayed active in politics and will continue to work with policy makers towards that goal.

Timothy R. Franson, M.D.

Timothy R. Franson, M.D., will be retiring 6/1/08 from the position of Vice President of Global Regulatory Affairs at Lilly Research Laboratories.  He joined Eli Lilly and Company in 1986, where he has previously served as Director of Anti-Infectives; Group Medical Director, Europe (based in the United Kingdom); Executive Director of Health Economics Research and Decision Sciences, Executive Director of Regulatory Affairs responsible for North American Regulatory, Chemistry Manufacturing Control, Planning & Global Operations (safety, labeling, medical information, registration and submissions) and from 1997-2003, Vice President of Clinical Research and Regulatory Affairs-US.  During his time in regulatory affairs, he has been directly responsible for Lilly’s FDA submissions (NDAs, supplements) since 1995, involving over 20 major submission reviews and approvals, and is now responsible for both Global Regulatory Affairs and Global Patient Safety organizations.  In 2002, he received the Lilly Chairman's Ovation Award.  He is also an Assistant Professor of Medicine at Indiana University School of Medicine.  

Franson received his undergraduate degree in Pharmacy (B.S. Pharm, honors) at Drake University, his M.D. degree (James Scholar, with honors) at the University of Illinois, and completed internal medicine training at the University of Iowa, followed by a fellowship in Infectious Diseases and Epidemiology at the Medical College of Wisconsin.  He is Board Certified in Internal Medicine and Infectious Diseases.  He was Assistant Professor of Medicine and Hospital Epidemiologist at the Medical College of Wisconsin where he was a NIH funded investigator and a member of the State of Wisconsin’s Governors Task Force on AIDS.  

Dr. Franson has authored over 50 articles and one text in the fields of infectious disease, epidemiology, pharmacoeconomics and antibiotic utilization.  He has served as chair of the Clinical Steering Committee and as a member of the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers’ Association (PhRMA) and until recently, chaired PhRMAs FDA Committee Staff Work Group (2000-2008) and previously chaired their GMP Steering Committee.  He was co-chair of the joint FDA-industry working group addressing clinical aspects of the FDA Modernization Act of 1997, including the Prescription Drug User Fee Act (PDUFA) renewal; and from 2000-2003 he co-chaired the overall industry-FDA committees for PDUFA-3 renewal and has testified at several congressional hearings representing industry.  He also co-chaired an FDA-industry safety interventions working group, was a member of the AAMC-PhRMA Clinical Trials Forum and is a member of the Regulatory Advisory Board for the Centre for Medicines Research International.  He previously served on the Board of Directors for the National Patient Safety Foundation (NPSF, 2001-2006) and on the Editorial Advisory Board for FDA Advertising & Promotional Manual (1997-2005).  Franson is now a member of the Board of Directors of the Villages of Indiana child welfare services (immediate past Chair), Little Red Door Cancer Agency Board of Directors, the Indiana State Museum Foundation, as well as the Board of Trustees of Xavier University of Louisiana and also serves on the American Association of Colleges of Pharmacy Professional Education Advisory Council.  He is a Fellow of the Infectious Diseases Society of America, a Fellow of the American College of Physicians, served on the European Working Party for Antimicrobial Trial Guidelines, and was principal respondent for industry at the FDA Advisory Committee review of the FDA/IDSA Antimicrobial Trial Guidelines project.  

Franson previously served on Drake University’s Task Force on the College of Pharmacy and Health Sciences and Dean's Council and is currently a member of the College of Pharmacy Dean's Advisory Board for Auburn University.  He has also been active in his community’s schools, serving previously as Chair of the School District Educational Master Plan Committee, and as a member of the Superintendent’s Advisory Board, and of the Athletic Booster Club Board. 

Jacob Arfwedson

Jacob Arfwedson, a native Swede, received his MA in social sciences from the Catholic University of Paris before receiving the Timbro Capitol Fellowship to study at the Catholic University of America (Washington D.C.).

He has worked as international press editor at the French Prime Minister's Information Office, Director of events and publications at the French free market think-tank Institut EURO 92, Research Director at the World Association of Newspapers, Managing Editor of the website, and Consultant in media relations at the OECD. He is currently a Research Fellow at the Stockholm Network (London), a pan-european organisation of more than 130 market-orientated think-tanks, and consultant to think tanks in Europe and the USA.

Tim Wilson

CMPI Senior Fellow Tim Wilson also serves as the Director of the Intellectual Property and Free Trade Unit at the Institute of Public Affairs in Melbourne, Australia. Tim has worked as a Trade and Senior Communication Consultant and as a Project Manager delivering aid and development projects throughout South East Asia. He has also advised state and federal Australian Members of Parliament. Tim has a Masters of Diplomacy and Trade and a Bachelor of Arts from Monash University. He has also studied IP at the WIPO Academy; and Global Health Diplomacy and the WTO, International Trade and Development at the Institut de Hautes Études Internationales et du Développment. Tim is a member of the Australian Foreign Affairs Department’s IP Industry Consultative Group. In 2009 he was recognised by Australia’s national daily newspaper, The Australian, as one of the ten emerging leaders of Australian society and is a recipient of an Australian Leadership Award.

Talya Miron-Shatz, PhD.

Talya Miron-Shatz is a decision scientist specializing in medical decision making. Her research examines people’s understanding of health information, and ways of improving it. An important focus of her work is on adherence to medication, and developing scientifically valid interventions for improving adherence through behavioral means. Her work is published in peer-reviewed journals and in books (MIT, Oxford University Press).

She has a PhD from the Hebrew University in social and experimental psychology, and spent five years at Princeton University, as post-doctoral fellowship at Princeton University with Nobel Laureate Daniel Kahneman. From 2008 - 2011 she taught consumer behavior at Wharton, University of Pennsylvania, with an emphasis on health consumerism. In addition to being a senior fellow at CMPI, Talya is an associate professor at the Ono Academic College, where she is founding director of the Center for Medical Decision Making. Dr. Miron-Shatz is CEO of CureMyWay, a start-up company developing personalized adherence solutions.
Her invaluable academic and industry experience makes her a sought after public speaker on behavior change. 
Her Psychology Today blog deals with issues such as 'does diet soda make you thin?'  and 'what do tattoos have to do with hemophilia?'

Sign Up for Our Email Newsletter


Product Failure Is Not Process Failure

Product Failure Is Not Process Failure

FDA be nimble. FDA be quick. FDA jump over the bureaucratic schtick....  Read more

New CMPI Book: And Nothing But the Truth

New CMPI Book: And Nothing But the Truth

Healthcare evolution, in technology and policy, is a never-ending parade of complicated and contradictory truths. This bo...  Read more

Sorry, but the ‘drugs from Canada’ don’t work

Sorry, but the ‘drugs from Canada’ don’t work

“Drugs from Canada” is a policy that won’t work. And a political soundbite that won’t die....  Read more